719 related articles for article (PubMed ID: 18154821)
1. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
3. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
6. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
[TBL] [Abstract][Full Text] [Related]
8. Soluble mesothelin-related protein--a blood test for mesothelioma.
Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789
[TBL] [Abstract][Full Text] [Related]
9. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
[TBL] [Abstract][Full Text] [Related]
10. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
12. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
Park EK; Sandrini A; Yates DH; Creaney J; Robinson BW; Thomas PS; Johnson AR
Am J Respir Crit Care Med; 2008 Oct; 178(8):832-7. PubMed ID: 18583574
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
Cristaudo A; Foddis R; Vivaldi A; Guglielmi G; Dipalma N; Filiberti R; Neri M; Ceppi M; Paganuzzi M; Ivaldi GP; Mencoboni M; Canessa PA; Ambrosino N; Chella A; Mutti L; Puntoni R
Clin Cancer Res; 2007 Sep; 13(17):5076-81. PubMed ID: 17785560
[TBL] [Abstract][Full Text] [Related]
14. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Landi D; Gemignani F; Landi S
Occup Environ Med; 2010 Apr; 67(4):233-6. PubMed ID: 19858537
[TBL] [Abstract][Full Text] [Related]
19. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
20. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]